DRD2 and neoplasm: Although there is very little preclinical evidence correlating DRD2 antagonism and response in DMG, there is in silico and in vitro modeling providing evidence that dordaviprone binds to GPCR, in a selective way.44 Additionally, there is little information into the interactions of other dopamine receptors, and how these may contribute to its anti-tumor effects.